Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Edoxaban (Lixiana) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr.
No patient group input was received by CDR for this submission.
- PATIENT INPUT - Edoxaban (Lixiana)PATIENT INPUT - Edoxaban (Lixiana)
- CADTH COMMON DRUG REVIEW ANALYSES - Omalizumab (Xolair)CADTH COMMON DRUG REVIEW ANALYSES - Omalizumab (Xolair)
- SUMMARY OF MANUFACTURER’S SENSITIVITY ANALYSES - Omalizumab (Xolair)SUMMARY OF MANUFACTURER’S SENSITIVITY ANALYSES - Omalizumab (Xolair)
- Pharmacoeconomic Review Report - Ingenol Mebutate (Picato)Pharmacoeconomic Review Report - Ingenol Mebutate (Picato)
- Picryl ChloridePicryl ChlorideA hapten that generates suppressor cells capable of down-regulating the efferent phase of trinitrophenol-specific contact hypersensitivity. (Arthritis Rheum 1991 Feb;34(2):180...<br/>Year introduced: 1965MeSH
Your browsing activity is empty.
Activity recording is turned off.
See more...